Meyka Pro banner
Novocure Ltd

Novocure Ltd Fundamental Analysis (NASDAQ: NVCR)

NVCRNASDAQ
HealthcareMedical - Devices
$17.65
$2.34(11.71%)
U.S. Market opens in 62h 18m

Novocure Ltd Fundamental Analysis (NASDAQ: NVCR)

Novocure Ltd (NASDAQ: NVCR) shows moderate financial fundamentals with a PE ratio of -14.09, profit margin of -21.25%, and ROE of -44.00%. The company generates $0.7B in annual revenue with moderate year-over-year growth of 8.28%.

Key Strengths

PEG Ratio-4.44

Areas of Concern

ROE-44.00%
Operating Margin-22.08%
Current Ratio0.00
We analyze NVCR's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -34.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-34.6/100

We analyze NVCR's fundamental strength across five key dimensions:

Efficiency Score

Weak

NVCR struggles to generate sufficient returns from assets.

ROA > 10%
0.00%

Valuation Score

Excellent

NVCR trades at attractive valuation levels.

PE < 25
-14.09
PEG Ratio < 2
-4.44

Growth Score

Excellent

NVCR delivers strong and consistent growth momentum.

Revenue Growth > 5%
8.28%
EPS Growth > 10%
21.79%

Financial Health Score

Moderate

NVCR shows balanced financial health with some risks.

Debt/Equity < 1
0.27
Current Ratio > 1
0.00

Profitability Score

Weak

NVCR struggles to sustain strong margins.

ROE > 15%
-4399.94%
Net Margin ≥ 15%
-21.25%
Positive Free Cash Flow
No

Key Financial Metrics

Is NVCR Expensive or Cheap?

P/E Ratio

NVCR trades at -14.09 times earnings. This suggests potential undervaluation.

-14.09

PEG Ratio

When adjusting for growth, NVCR's PEG of -4.44 indicates potential undervaluation.

-4.44

Price to Book

The market values Novocure Ltd at 6.29 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

6.29

EV/EBITDA

Enterprise value stands at -15.12 times EBITDA. This is generally considered low.

-15.12

How Well Does NVCR Make Money?

Net Profit Margin

For every $100 in sales, Novocure Ltd keeps $-21.25 as profit after all expenses.

-21.25%

Operating Margin

Core operations generate -22.08 in profit for every $100 in revenue, before interest and taxes.

-22.08%

ROE

Management delivers $-44.00 in profit for every $100 of shareholder equity.

-44.00%

ROA

Novocure Ltd generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.

0.00%

Following the Money - Real Cash Generation

Operating Cash Flow

Novocure Ltd generates limited operating cash flow of $-2.81M, signaling weaker underlying cash strength.

$-2.81M

Free Cash Flow

Novocure Ltd generates weak or negative free cash flow of $-25.39M, restricting financial flexibility.

$-25.39M

FCF Per Share

Each share generates $-0.22 in free cash annually.

$-0.22

FCF Yield

NVCR converts -1.22% of its market value into free cash.

-1.22%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-14.09

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-4.44

vs 25 benchmark

P/B Ratio

Price to book value ratio

6.29

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.03

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.27

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.00

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.44

vs 25 benchmark

ROA

Return on assets percentage

0.00

vs 25 benchmark

ROCE

Return on capital employed

0.70

vs 25 benchmark

How NVCR Stacks Against Its Sector Peers

MetricNVCR ValueSector AveragePerformance
P/E Ratio-14.0929.34 Better (Cheaper)
ROE-44.00%470.00% Weak
Net Margin-21.25%-11436.00% (disorted) Weak
Debt/Equity0.270.84 Strong (Low Leverage)
Current Ratio0.005.17 Weak Liquidity
ROA0.00%-23.00% (disorted) Weak

NVCR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Novocure Ltd's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

20.03%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-722.70%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-144.78%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ